AI Drug Discovery: Opening a New Path with Supercomputing
Drug discovery is both the frontline of medicine and one of its most arduous journeys.
It takes years and billions of dollars to bring a new drug to market, with success rates often below 10%.
But this paradigm is changing—thanks to AI and supercomputing.
At the center of this transformation stands Syntekabio, preparing to go beyond being a technology provider
and step into a new role as an Early-Stage AI Drug Discovery CDMO*.
(*Contract Development and Manufacturing Organization)
The key to this vision is the AI Supercomputing Center currently under construction in Daejeon’s Dungok District.
What Is an Early-Stage AI Drug Discovery CDMO?
The concept of a CDMO is well established in the pharmaceutical industry,
where companies outsource entire phases of drug development and manufacturing to specialized organizations.
In Korea, global players such as Samsung Biologics and Celltrion are leading examples.
Now, this model is being applied to AI drug discovery.
If the entire early-stage pipeline—target identification → hit discovery → lead optimization → toxicity assessment → preclinical studies
—can be offered as a one-stop outsourced service, pharmaceutical companies can focus on expanding their pipelines and commercialization.
However, existing global AI companies still struggle with standardization and scalability.
While they may have data and algorithms, they often lack the infrastructure to run drug discovery simulations at industrial scale.
Syntekabio is solving this gap with two proven platforms:
DeepMatcher®: AI-driven hit discovery platform
STB CLOUD: The world’s first cloud-based AI drug discovery platform
Together, these platforms address both scalability and standardization challenges.
The Three Pillars of AI Drug Discovery
Efficient AI drug discovery requires three essential pillars:
AI Algorithms – the intelligent engine for molecule discovery and drug design
Supercomputing Infrastructure – computational power to handle billions of simulations
Cloud Platform – global accessibility without physical or geographical limitations
Even with strong algorithms, without sufficient supercomputing power, execution is impossible
—just as high-end games cannot run on low-spec PCs.
Syntekabio has secured all three pillars:
Operating around 3,000 supercomputers today, expanding to 10,000 units with the new center
Providing STB CLOUD to enable seamless global access for pharmaceutical partners
Global Landscape and Syntekabio’s Differentiation
Biotech startups worldwide are entering the AI drug discovery market, many highlighting their algorithms for hit discovery.
But algorithms alone are not enough.
AI drug discovery requires massive-scale simulations, and without supercomputing, reliable outcomes cannot be achieved.
Real drug discovery becomes possible only when algorithms + hardware + cloud form a complete ecosystem.
Syntekabio differentiates itself with:
Verified platforms (DeepMatcher® + STB CLOUD)
Unmatched computing power via the new Supercomputing Center
Cloud infrastructure enabling global scalability
Syntekabio’s Vision: Early-Stage AI Drug Discovery CDMO
Syntekabio is preparing to evolve into more than a technology provider—becoming a trusted partner to global pharma.
The company aims to position itself as an Early-Stage AI Drug Discovery CDMO,
capable of handling the entire early phase (target identification → hit discovery → lead optimization → toxicity → preclinical studies) on behalf of clients.
In this model, pharma companies focus on pipelines and commercialization,
while Syntekabio leverages AI and supercomputing to take responsibility for the foundations of drug development.
Just as Samsung Biologics has become indispensable in the biopharma CDMO space,
Syntekabio envisions becoming the equivalent in the AI-driven drug discovery industry.
✅ In summary,
The core of AI drug discovery lies in AI + Supercomputing + Cloud.
Syntekabio is one of the few companies that has secured all three pillars.
Its goal is to establish itself as an Early-Stage AI Drug Discovery CDMO,
leading the industry in partnership with global pharmaceutical companies.
AI drug discovery is no longer an experimental concept but a paradigm that has become reality.
At the center of this transformation stands Syntekabio, powered by supercomputing and cloud.
🔗 Open Link
[Feature] Syntekabio Draws the Future of “AI Drug Discovery Pipeline & Drug Repurposing” <3>
